Patents by Inventor Surinder K. Sharma

Surinder K. Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified carboxypeptidase enzymes and their use
    Patent number: 6656718
    Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: December 2, 2003
    Assignee: Cancer Research Technology Limited
    Inventors: Richard H. J. Begent, Kerry Chester, Nigel P. Minton, Anthony R. Rees, Surinder K. Sharma, Daniel I. R. Spencer
  • Modifided carboxypeptidase enzymes and their use
    Publication number: 20020090709
    Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.
    Type: Application
    Filed: July 5, 2001
    Publication date: July 11, 2002
    Inventors: Richard H. J. Begent, Kerry Chester, Nigel P. Minton, Anthony R. Rees, Surinder K. Sharma, Daniel I. R. Spencer
  • Method for the treatment of tumors with conjugated antibody A5B7 and a prodrug
    Patent number: 5683694
    Abstract: A method for treatment of tumors to which antibody A5B7 binds is disclosed. A5B7 is a monoclonal antibody which binds to carcinoembryonic antigen. The method comprises administering to a host in need of such treatment an effective amount of a system which comprises a conjugate comprising: antibody A5B7 or a humanized version of A5B7 linked to an enzyme selected from the group consisting of carboxypeptidase G2 (CPG2), nitroreductase, a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody; and a prodrug convertible under the influence of the conjugate into a cytotoxic drug.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 4, 1997
    Assignee: Cancer Research Campaign Tech. Ltd. & Zeneca Ltd.
    Inventors: Kenneth D. Bagshawe, Gordon T. Rogers, Surinder K. Sharma
  • Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
    Patent number: 5632990
    Abstract: A treatment for tumors to which antibody A5B7 binds is disclosed. A5B7 is a monoclonal antibody which binds to carcinoembryonic antigen. The treatment comprises administering to a host in need of such treatment an effective amount of a system which comprises: a conjugate comprising antibody A5B7 or a humanized version of A5B7 linked to an enzyme selected from the group consisting of carboxypeptidase G2 (CPG2), nitroreductase, a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody; and a prodrug convertible under the influence of the conjugate into a cytotoxic drug.
    Type: Grant
    Filed: September 28, 1994
    Date of Patent: May 27, 1997
    Assignees: Cancer Research Campaign Tech. Ltd., Zeneca Ltd.
    Inventors: Kenneth D. Bagshawe, Gordon T. Rogers, Surinder K. Sharma